Form 4: Director Robert Epstein Sells 10,000 Veracyte Shares
Statement of Changes in Beneficial Ownership
Veracyte, Inc. Director Robert S. Epstein sold 10,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.
Summary
- Director Robert S. Epstein sold 10,000 shares of Veracyte, Inc. (VCYT) common stock.
- The shares were sold at a weighted average price of $44.0129 per share.
- The transaction was executed on May 20, 2026.
- Following the sale, the director retains beneficial ownership of 52,446 shares.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a routine divestment by an insider.
Positives
- The transaction was executed under a pre-established Rule 10b5-1 plan, indicating the sale was planned in advance rather than a reactive move to current market conditions.
Negatives
- The sale represents a reduction in the director's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by retail investors as a signal of management's view on current valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Management Comments
- The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025.
Industry Context
StockSavvy.ai notes that director sales executed under Rule 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not reflect a change in sentiment regarding the company's long-term prospects.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential accusations of insider trading.
Stakeholder Impact
- Minimal impact expected as the sale was conducted via a pre-arranged plan.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-05 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2026-05-20 | Date of the reported stock sale transaction. |
| 2026-05-22 | Date the Form 4 was signed and filed. |
Keywords
Veracyte, VCYT, Insider Trading, Form 4, Director Sale, Equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.